Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 10/20 | 0.42 |
| ▸ | CDK8 | P49336 | 10/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30428285 | 0.89 | CHRM1 (0.45) | CHRM1PIM1PIM2CCNCCDK8 | |
| SCHEMBL21873385 | 0.89 | CHRM1 (0.45) | CHRM1PIM1PIM2CCNCCDK8 | |
| SCHEMBL21873400 | 0.89 | CHRM1 (0.49) | CHRM1PIM1PIM2GRM2 | |
| SCHEMBL30428359 | 0.89 | CHRM1 (0.49) | CHRM1PIM1PIM2GRM2 | |
| SCHEMBL19932608 | 0.87 | CHRM1 (0.45) | CHRM1PIM1PIM2CCNCCDK8 | |
| SCHEMBL21873392 | 0.84 | BRD4 (0.38) | CHRM1 | |
| SCHEMBL30427563 | 0.84 | BRD4 (0.38) | CHRM1 | |
| SCHEMBL21873510 | 0.84 | PPARG (0.35) | CHRM1CCNCCDK8 | |
| SCHEMBL30428257 | 0.84 | PPARG (0.35) | CHRM1CCNCCDK8 | |
| SCHEMBL21873442 | 0.84 | CHRM1 (0.47) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378256-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| EP-3643718-B1 | HETEROCYCLIC COMPOUND AND ITS USE AS POSITIVE ALLOSTERIC MODULATOR OF THE CHOLINERGIC MUSCARINIC M1 RECEPTOR. | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-110709401-B | Heterocyclic compounds | 武田药品工业株式会社 | 2023-06-13 | — | — | CN | disclosed |
| US-11236099-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| EP-3643718-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-04-29 | — | — | EP | disclosed |
| CN-110709401-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | SLC10A2, ALPI, VIP | CHRM1 817/4885PIM1 4730/4885PIM2 4700/4885 |
| US-12378256-B2 | Heterocyclic compound | SLC10A2, ALPI, VIP | CHRM1 817/4885PIM1 4730/4885PIM2 4700/4885 |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | SLC10A2, ALPI, VIP | CHRM1 817/4885PIM1 4730/4885PIM2 4700/4885 |
| US-11236099-B2 | Heterocyclic compound | SLC10A2, ALPI, VIP | CHRM1 817/4885PIM1 4730/4885PIM2 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.